Latest From GlaxoSmithKline PLC
GlaxoSmithKline's new CEO is assembling a "dream team" to rebuild the big pharma's R&D pipeline with an emphasis on building in oncology. Walmsley outlined her strategy at J.P. Morgan, while Oncology Therapy Area Head Axel Hoos provided more details in an interview.
Longitudinal observational study of NASH patients provides data to companies to help them better understand disease; Target PharmaSolutions conducting similar efforts in primary biliary cholangitis, hepatocellular carcinoma, and inflammatory bowel disease.
US scale-up plans, cost optimization and a deeper push in certain other markets to garner volumes and as a buffer against volatility were some of the key strategies discussed by Cipla’s CEO at the recent J.P. Morgan Healthcare Conference in San Francisco.
Biopharma investors were underwhelmed by the deal-making news, but innovation, corporate tax reform and a relatively positive outlook on drug pricing left attendees at the J.P. Morgan Healthcare Conference with the sense that good things are in store for pharma in 2018.
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Western Europe
- Company Type
- Big Pharma
- Parent & Subsidiaries
- Affymax NV
- AKE Pathologists
- Allen & Hanburys Ltd.
- American Medical Optics
- Block Drug Co. Inc.
- Bristol-Myers Squibb Pakistan Ltd.
- Burroughs Wellcome Co.
- Burroughs Wellcome Inc.
- Cellzome AG
- Center of Excellence for External Drug Discovery
- CNS Inc.
- Corixa Corp.
- Diversified Prescription Delivery
- Domantis Ltd.
- Galvani Bioelectronics
- Genelabs Technologies Inc.
- Glaxo Australia Pty. Ltd.
- Glaxo Canada-IAF Biochem Joint Venture
- Glaxo Group Research Ltd.
- Glaxo Hong Kong
- Glaxo Laboratories Ltd.
- Glaxo Research and Development Ltd.
- Glaxo Wellcome Inc.
- Glaxo Wellcome PLC
- Glaxo Wellcome SA
- Glaxo Wellcome SPA
- GlaxoSmithKline (China) Investment Co. Ltd.
- GlaxoSmithKline Biologicals SA
- GlaxoSmithKline Consumer Healthcare LP
- GlaxoSmithKline Inc.
- GlaxoSmithKline KK
- GlaxoSmithKline LLC
- GlaxoSmithKline Pharmaceuticals Ltd.
- GlycoVaxyn AG
- GSK Biologicals Shenzhen Co. Ltd.
- Human Genome Sciences Inc.
- ID Biomedical Corp.
- International Clinical Laboratories Inc.
- International Hydron Corp.
- Laboratorios Phoenix SA
- Lombart Optical of Virginia Ltd.
- Maxinutrition Group Holdings Ltd.
- Morrith SA
- Nanjing MeiRui Pharma Co. Ltd
- Nippon Glaxo Co. Ltd.
- Norcliff Thayer and Reheis
- Okairos AG
- Pathology and Cytology Laboratories
- Polfa Poznan SA
- Praecis Pharmaceuticals Inc.
- Puget Sound Institute of Pathology Inc.
- Reliant Pharmaceuticals Inc.
- Sachsisches Serumwerk GMBH
- Sirtris Pharmaceuticals Inc.
- SmithKline Beecham
- SmithKline Beecham Animal Health
- SmithKline Beecham Consumer Healthcare
- SmithKline Beecham Corp.
- SmithKline Beecham Healthcare Services
- SmithKline Beecham Pharmaceuticals
- SmithKline Beecham Pharmaceuticals R&D
- SmithKline Beecham Seiyaku KK
- SmithKline Bio-Science Laboratories
- SmithKline Diagnostics Inc.
- Softsite Contact Lens Laboratory Inc.
- Stiefel Research Australia Pty. Ltd.
- Total Support Management Group
- ViiV Healthcare
- Visiontech Inc.
- Wellcome Biotechnology Ltd.
- Wellcome Diagnostics
- Wellcome Foundation Ltd.
- Zambeletti SPA
- Senior Management
Brian McNamara, CEO, GSK Consumer Healthcare
Simon Dingemans, CFO
Patrick Vallance, Pres., Pharma R&D
Abbas Hussain, Pres., Global Pharmaceuticals
Luc Debruyne, Pres., Global Vaccines
David Redfern, Chief Strategy Officer
- Contact Info
Phone: (44) (0)20 8047 5000
980 Great West Rd.
Brentford, TW8 9GS
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.